Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2471 to 2480 of 2582 total matches.

In Brief: Oral Propranolol for Infantile Hemangiomas

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2011  (Issue 1376)
. No significant hypoglycemia, hypotension or bradycardia occurred.3 1. C Léauté-Labrèze et al. Propranolol ...
The surprising observation that oral administration of the beta-blocker propranolol (Inderal, and others) can stop the growth and rapidly cause the involution of disfiguring or life-threatening infantile hemangiomas1 has quickly led to a series of confirmatory observations and now a controlled trial. The mechanism of this effect is not known, but is thought to be related to down-regulation of the RAF mitogen-activated protein kinase signaling pathway resulting in inhibition of vascular endothelial growth factor (VEGF) and apoptosis in capillary endothelial cells. The response of infantile...
Med Lett Drugs Ther. 2011 Oct 31;53(1376):88 |  Show IntroductionHide Introduction

Lasik and Its Alternatives: An Update

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004  (Issue 1174)
-threatening infection after LASIK is 1 to 5 per 10,000 procedures. About 3% of patients who have had LASIK ...
Since the last Medical Letter article on surgical correction of refractive errors (Volume 41, page 122, 1999), some new techniques have been tried and new results have been reported.
Med Lett Drugs Ther. 2004 Jan 19;46(1174):5-7 |  Show IntroductionHide Introduction

Gabapentin (Neurontin) for Chronic Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 12, 2004  (Issue 1180)
with gabapentin and 3.5 with placebo, compared to 4.2 and 4.1 at baseline. A reduction of at least 50% in the 4 ...
Gabapentin (Neurontin - Pfizer), which has been available in the US since 1994, is approved by the FDA only for treatment of partial epilepsy and postherpetic neuralgia, but is widely used off-label for a number of other indications, especially neuropathic pain syndromes. According to one report, among Medicaid recipients in Florida receiving gabapentin, 71% of prescriptions were for chronic pain and 8% for seizures and neuralgia ("The Pink Sheet" February 2, 2004; 66:30).
Med Lett Drugs Ther. 2004 Apr 12;46(1180):29-31 |  Show IntroductionHide Introduction

Performance-Enhancing Drugs

   
The Medical Letter on Drugs and Therapeutics • Jul 19, 2004  (Issue 1187)
Med 1996; 335:1). Anabolic steroids are synthetic derivatives of testosterone; all retain some ...
With the 2004 Olympics only weeks away, performance-enhancing drugs will once again be receiving a great deal of attention. The US Anti-Doping Agency has published a list of drugs banned in Olympic sports (www.usantidoping.org) that includes, at least for some sports, all but 2 of the drugs reviewed here.
Med Lett Drugs Ther. 2004 Jul 19;46(1187):57-9 |  Show IntroductionHide Introduction

Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
nonsmall cell lung cancer (NSCLC). Gefitinib (Iressa) was the first. 1 Both are approved only ...
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
Med Lett Drugs Ther. 2005 Mar 28;47(1205):25-6 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
mg/day over 4 wks: wk 1: 25 mg in the evening; wk 2: 25 mg in the morning and evening; wk 3: 25 ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2   doi:10.58347/tml.2023.1678c |  Show IntroductionHide Introduction

Alprazolam For Panic Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Alprazolam (Xanax - Upjohn), a triazolobenzodiazepine previously available in the USA for treatment of anxiety (Medical Letter 24:41, 1982), was recently approved by the US Food and Drug Administration (FDA) for treatment of panic disorder, with or without agoraphobia. According to one report, alprazolam was the fifth most widely prescribed drug in the USA last year (American Medical News, March 4, 1991, page 4).
Med Lett Drugs Ther. 1991 Apr 5;33(841):30-1 |  Show IntroductionHide Introduction

Prostate Specific Antigen

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 1992  (Issue 880)
. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Serum measurements of prostate specific antigen (PSA) are now being used in the diagnosis and management of prostate cancer. Produced by prostatic epithelium, PSA is a protease involved in liquefaction of the seminal coagulum. Whether this test should be used for routine screening is a matter of controversy; it is currently approved by the US Food and Drug Administration (FDA) only for monitoring after treatment for prostate cancer.
Med Lett Drugs Ther. 1992 Oct 2;34(880):93-4 |  Show IntroductionHide Introduction

Transdermal Fentanyl

   
The Medical Letter on Drugs and Therapeutics • Oct 16, 1992  (Issue 881)
resulting from any error, inaccuracy or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1 ...
Fentanyl, a synthetic opioid previously available for parenteral use in anesthesia (Sublimaze), has now been marketed in a controlled-release transdermal formulation (Duragesic - Janssen) for use in patients with chronic pain severe enough to require opioid analgesia. It is not recommended for treatment of postoperative pain because of the drug's slow onset and prolonged duration of action.
Med Lett Drugs Ther. 1992 Oct 16;34(881):97-8 |  Show IntroductionHide Introduction

Teniposide for Acute Lymphoblastic Leukemia

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 1992  (Issue 883)
. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of refractory acute lymphoblastic leukemia (ALL) in children. A semisynthetic derivative of podophyllotoxin, teniposide is chemically related to etoposide (VePesid - Medical Letter, 26:48, 1984).
Med Lett Drugs Ther. 1992 Nov 13;34(883):105-6 |  Show IntroductionHide Introduction